BASE,Inc. (TYO:4477)

CTI BioPharma Cash Flow Statement

Financials in millions JPY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	335	-71	-602	-1,735	-1,218	747
Depreciation & Amortization	33	30	2	49	45	42
Loss (Gain) From Sale of Assets	-	867	130	157	-	-
Loss (Gain) From Sale of Investments	-	-	63	83	258	-
Other Operating Activities	-538	16	-	88	-195	-6
Change in Accounts Payable	2,577	17,426	1,443	-973	3,756	5,070
Change in Other Net Operating Assets	189	-14,611	-1,116	625	-864	-2,725
Operating Cash Flow	2,079	3,657	-80	-1,706	1,782	3,128
Operating Cash Flow Growth	-	-	-	-	-43.03%	259.54%
Capital Expenditures	-17	-26	-53	-28	-20	-32
Cash Acquisitions	-3,413	-87	-	-	-	-
Sale (Purchase) of Intangibles	-	-	-	-	-1	-2
Investment in Securities	-	-	-	-	-	-436
Other Investing Activities	-102	-46	-	-	-	-1
Investing Cash Flow	-3,532	-159	-53	-28	-21	-471
Long-Term Debt Repaid	-	-10	-	-	-	-
Net Debt Issued (Repaid)	-30	-10	-	-	-	-
Issuance of Common Stock	22	13	16	26	21	12,419
Financing Cash Flow	-1,015	3	16	26	21	12,419
Miscellaneous Cash Flow Adjustments	-	1	-	-	-	-
Net Cash Flow	-2,468	3,502	-117	-1,708	1,782	15,076
Free Cash Flow	2,062	3,631	-133	-1,734	1,762	3,096
Free Cash Flow Growth	-	-	-	-	-43.09%	266.39%
Free Cash Flow Margin	11.58%	22.72%	-1.14%	-17.80%	17.74%	37.35%
Free Cash Flow Per Share	17.66	30.90	-1.16	-15.47	15.93	27.59
Cash Interest Paid	10	3	-	-	-	-
Cash Income Tax Paid	206	4	4	-63	201	7
Levered Free Cash Flow	-	3,346	5.38	-1,181	2,054	2,938
Unlevered Free Cash Flow	-	3,348	5.38	-1,181	2,054	2,938
Change in Working Capital	1,084	2,815	327	-348	2,892	2,345

Source: S&P Global Market Intelligence. Standard template. Financial Sources.